Tacrolimus Treatment for Refractory PRCA
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03540472|
Recruitment Status : Unknown
Verified May 2018 by Bing Han, Peking Union Medical College Hospital.
Recruitment status was: Recruiting
First Posted : May 30, 2018
Last Update Posted : May 30, 2018
|Condition or disease||Intervention/treatment||Phase|
|Pure Red Cell Aplasia||Drug: tacrolimus||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study|
|Estimated Study Start Date :||June 10, 2018|
|Estimated Primary Completion Date :||December 10, 2018|
|Estimated Study Completion Date :||June 10, 2020|
Experimental: efficiency of tacrolimus on PRCA
A prospective research of the tacrolimus efficiency on refractory PRCA patients On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.
Medication time should last at least 6 months.
On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
Other Name: tacrolimus capsule
- Hemoglobin level [ Time Frame: 6 months ]Hemoglobin level in g/L
- Hemoglobin level [ Time Frame: 2 years ]Hemoglobin level in g/L
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03540472
|Contact: Zhangbiao Long, M.D.||+86 firstname.lastname@example.org|
|Contact: Hongmin Li, M.D.||+86 email@example.com|
|Peking Union Medical College Hospital||Recruiting|
|Beijing, Beijing, China, 100730|
|Contact: Zhangbiao Long, M.D. +86 13011826728 firstname.lastname@example.org|